KRAS and colorectal carcinoma: To identify clinical therapeutic compounds active in KRAS mutant CRC cells, we performed an in vitro screening using a customized natural product library to assess drug sensitivity in KRAS wild-type cells (HT29, HCT8, RKO), KRASG12D (LS180), KRASG12V (SW480), and KRASG13D (HCT116) mutant cells (Figure 1A).